ArticleNeurosurgical review2026
External validation of the VALE scoring system for hemorrhage risk in pediatric AVM patients.
Article in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain arteriovenous malformations (AVMs) are the leading cause of spontaneous intracranial hemorrhage in children. The recently developed VALE scoring system has demonstrated predictive value for hemorrhage risk in adult AVM patients; however, its applicability to pediatric populations remains unknown. We performed a retrospective analysis of a prospectively maintained vascular database at University Hospital Frankfurt. Pediatric patients (≤ 18 years) diagnosed with a single brain AVM between 2005 and 2023 were included. VALE scores were calculated according to the original model using ventricular system involvement, associated venous aneurysms, deep location, and exclusively deep venous drainage. Logistic regression analyses were performed to evaluate associations with hemorrhagic presentation. Discriminatory performance was assessed using receiver operating characteristic (ROC) analysis. A total of 52 pediatric AVM patients were included, of whom 31 (60%) presented with hemorrhage. Associated venous aneurysms were observed in 29% of ruptured AVMs compared with 5% of unruptured lesions and represented the only VALE component that remained significant in multivariable analysis. The complete VALE score demonstrated limited discriminatory performance, yielding an area under the ROC curve (AUC) of 0.608 (95% CI 0.454-0.762). Classification into VALE-defined risk categories showed similarly limited predictive ability (AUC 0.545, 95% CI 0.390-0.700), with no significant increase in hemorrhage risk across risk groups. This study represents the first external validation of the VALE scoring system in a pediatric AVM cohort. In our population, the VALE score demonstrated limited discriminatory performance and could not be conclusively validated. While associated venous aneurysms remained associated with hemorrhagic presentation, larger multicenter studies are required to further evaluate the applicability of the VALE score in pediatric patients and to determine whether pediatric-specific hemorrhage risk prediction models may be beneficial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.